NCT06477419 A Study of Sacituzumab Govitecan in People With Mesothelioma Status RECRUITING Phase PHASE2
NCT06452160 A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors Status RECRUITING Phase PHASE1
NCT06090318 Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss Status WITHDRAWN Phase PHASE1/PHASE2
NCT06057935 A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma Status RECRUITING Phase PHASE2
NCT06051695 A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression Status RECRUITING Phase PHASE1/PHASE2
NCT06034860 Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types Status TERMINATED Phase PHASE1
NCT05960773 Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma Status SUSPENDED Phase PHASE2
NCT05932199 Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma Status RECRUITING Phase PHASE1/PHASE2
NCT05873686 A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers Status RECRUITING Phase PHASE1
NCT05819580 Studying the Clinical Trial Experiences of Patients With Mesothelioma Status NOT_YET_RECRUITING Phase N/A
NCT05730816 MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI Status RECRUITING Phase PHASE2
NCT05627960 First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies Status RECRUITING Phase PHASE1
NCT05579366 Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) Status RECRUITING Phase PHASE1/PHASE2
NCT05571839 A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT05544929 A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT05461430 Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) Status COMPLETED Phase N/A